![](https://library.celltelligence.com/wp-content/uploads/2022/02/GSK_earnings.png)
$0
Lete-cel’s Readout Anticipated For 2023; New GSK Expected to Launch by Mid-2022; GSK’s Q4 2021 Earnings Call Summary
On Wednesday, February 9, GSK held their Q4 2021 earnings call (press release / presentation). Of note, management presented lete-cel’s (NY-ESO-1 TCR-T) upcoming clinical updates and highlighted that GSK’s business separation is anticipated by mid-2022. Below, Celltelligence provides insights on potential approval timelines for lete-cel and how it compares to Adaptimmune’s afami-cel (MAGE-A4 SPEAR-T).